GSK Takes on 3 More Prosensa Exon-Skipping DMD Drugs.

BioWorld International Correspondent

Prosensa Therapeutics BV and GlaxoSmithKline plc are moving forward with three additional exon-skipping antisense oligonucleotides as part of their alliance in Duchenne's muscular dystrophy (DMD).

London-based GSK had gained options on the three compounds, PRO044, PRO045 and PRO053, under the potential [pounds sterling]428 million (US$675 million) alliance it entered with Leiden, the Netherlands-based Prosensa almost two years ago. (See BioWorld International, Oct. 14, 2009.)

The lead compound from that pact, PRO051, began a 48-week Phase III trial earlier this year. PRO051 addresses about 13 percent of the DMD …